Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Go back to Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
(NASDAQ: MIST) Delayed: 0.80 +0.04 (5.26%)
Previous Close $0.76    52 Week High $ 
Open $0.78    52 Week Low $ 
Day High $0.81    P/E N/A 
Day Low $0.74    EPS $ 
Volume 831,107